Clearblue False Positives Hit 1.7% of Kansas Abortion Clinic Patients
A Kansas doctor reports that 1 in 60 patients at her clinic have a false positive Clearblue test, leading to wasted travel and emotional strain for women traveling from abortion-restrictive states.
Key Takeaways
- A Kansas doctor reports that 1 in 60 patients at her clinic have a false positive Clearblue test, leading to wasted travel and emotional strain for women traveling from abortion-restrictive states.
Mentioned
Key Intelligence
Key Facts
- 1Dr. Sheila Attaie reports seeing a patient with a false positive pregnancy test every other day at a Kansas clinic that sees around 30 patients daily.
- 2All false positive cases identified by the doctor were from the Clearblue brand, the No. 1-selling home pregnancy test globally.
- 3One patient from Texas incurred $750 in costs, a 10-hour drive, and childcare arrangements—only to discover she was never pregnant.
- 4Many patients in abortion-restrictive states skip local doctor visits to avoid documentation, relying solely on home tests like Clearblue.
- 5Clearblue markets itself as over 99% accurate and was voted the 'most trusted brand' of 2025 by consumers.
She didn’t believe me. I had to spend a lot of time with her, showing her the ultrasound images, showing her the urine pregnancy test, and looking at the results together because she was in pure disbelief.
Conversations at Kansas abortion clinic
Dr. Attaie sees a false positive Clearblue test every other day among roughly 30 daily patients.
Analysis
For women in states with near-total abortion bans, a home pregnancy test is not just a diagnostic tool—it's the gatekeeper to an expensive and often clandestine journey for care. New data from a Kansas clinic suggests that the leading brand, Clearblue, may be producing false positives at a rate of 1.7%, posing a direct threat to patient safety and healthcare equity.
A troubling pattern has emerged at a Kansas abortion clinic where Dr. Sheila Attaie, a family medicine physician providing part-time care, reports that patients are arriving with false positive home pregnancy tests after arduous journeys from abortion-restrictive states. In every case, the brand identified is Clearblue, the world's top-selling pregnancy test. One particularly harrowing account involves a patient from Texas who scraped together $750, rented a car, found childcare for three children, and drove 10 hours across state lines—only to learn she had never been pregnant. Dr. Attaie estimates she sees such a false positive every other day among roughly 30 daily patients, implying a false positive rate of approximately 1.7% in this high-stress, self-testing population.
Clearblue dominates a global home pregnancy test market valued at roughly $1.5 billion, with a share exceeding 40%.
The implications are far-reaching in a post-Dobbs healthcare landscape where many women in states with abortion bans avoid clinical visits to prevent documentation of a pregnancy. For them, the at-home test becomes the sole diagnostic gatekeeper before a costly and emotionally fraught trip. While Clearblue markets itself as 'over 99% accurate' and remains the '#1 OB-GYN recommended brand' voted 'most trusted' in 2025, these anecdotes suggest a potential discrepancy between laboratory-controlled accuracy and real-world performance—especially when tests are taken early or under anxiety. The risk of false positives in this context causes not just inconvenience but tangible financial loss, unnecessary travel, and profound emotional distress.
What to Watch
The story also carries significant commercial implications. Clearblue dominates a global home pregnancy test market valued at roughly $1.5 billion, with a share exceeding 40%. A pattern of brand-specific false positives, even if anecdotally reported, could erode consumer trust, shifting purchases to competitors like First Response or digital-test brands. Retailers may face pressure to offer comparative accuracy data at the point of sale. On the regulatory front, the U.S. Food and Drug Administration classifies home pregnancy tests as Class II devices requiring 510(k) clearance, with limited post-market surveillance. This case may reignite debates about the adequacy of real-world performance monitoring for widely used over-the-counter diagnostics, particularly in vulnerable populations.
For healthcare providers, the report underscores an urgent need for patient education about the limits of home testing and the importance of confirmatory clinical visits when safe. For the manufacturer, which is produced by Swiss Precision Diagnostics (a P&G–Abbott joint venture), addressing the issue—whether through enhanced labeling, lot-specific investigations, or public reaffirmation of accuracy—will be critical to maintaining both brand equity and patient safety. Forward-looking, the convergence of reproductive rights politics and medical device reliability puts Clearblue at the center of a story with implications for corporate reputation, regulatory policy, and the lived experience of patients navigating a fractured care system. Whether this cluster of false positives represents a systemic quality lapse or an expected tail of test sensitivity remains to be determined, but the human cost already makes it impossible to ignore.
Sources
Sources
Based on 3 source articles- Alanna Vagianos (in)They Had Positive Pregnancy Tests — Without Ever Being Pregnant. The Brand Was Always The Same.Jun 13, 2026
- Alanna Vagianos (us)They Had Positive Pregnancy Tests — Without Ever Being Pregnant. The Brand Was Always The Same.Jun 13, 2026
- Alanna Vagianos (in)They Had Positive Pregnancy Tests — Without Ever Being Pregnant. The Brand Was Always The Same.Jun 13, 2026
Cite This Page
"Clearblue False Positives Hit 1.7% of Kansas Abortion Clinic Patients." Healthcare Intelligence Brief, June 14, 2026. https://gethealthbrief.com/story/clearblue-false-positives-health-clinic
How we covered this story
Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled healthcare-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |